Eissa et al., in a study published in the current issue of the in Afro-Egypt J Infect Endem Dis entitled "Liver Fibrosis Assessment in Cases of Chronic Hepatitis C after Direct Acting Antivirals Therapy using Aspartate Aminotransferase to Platelet Ratio Index and Transient Elastography" evaluated  changes in liver fibrosis among chronic HCV  patients after DAAs therapy using fibroscan  and APRI. They compared the scores of each patient before and one year after a full course of DAAs therapy. They found that liver stiffness measurement was markedly decreased from 10.6 to 6 kPa after 12 months of completion of DAAs therapy, with significant reduction of stage of fibrosis in more than 76% of their patients. The reduction of fibrosis stages had occurred in 87.50% of patients with F2 stage, 87.5% of patients with F3 stage, and 76.5% of patients with F4 stage. A relevant study on 300 Egyptian HCV patients showed reduction in fibrosis in; 46.7% and 49.3% of patients with moderate fibrosis, and 89% and 78.7% of patients with advanced fibrosis after one year of interferon containing and interferon free DAAs regimens respectively  which emphasize a significant reduction of LSM after DAAs therapy.